ETI 210

Drug Profile

ETI 210

Alternative Names: ETI-210

Latest Information Update: 05 Dec 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Elusys Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Complement activation stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 04 Jul 2005 Data presented at the BIO 2005 Annual International Convention (BIO-2005) have been added to the adverse events and Cancer pharmacodynamics section
  • 09 May 2005 EluSys Therapeutics has completed preclinical studies in Non-Hodgkin's lymphoma
  • 06 Jul 2004 Data presented at the 40th Annual Meeting of the American Society of Clinical Oncology (ASCO-2004) have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top